Compare Crispr Therapeutics AG (CRSP) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Star Bulk Carriers Corp — how do they compare? Crispr Therapeutics AG trades at $54.03 (market cap $5.23B), while Star Bulk Carriers Corp trades at $27.91 (market cap $3.09B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Star Bulk Carriers Corp pays a 6.79% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | SBLK | |
|---|---|---|
Market Cap | $5.23B | $3.09B |
Sector | Health | Industrials |
52-Week High | $76.78 | $29.15 |
52-Week Low | $44.34 | $16.79 |
Enterprise Value | $3.65B | $3.77B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Star Bulk Carriers (SBLK) trades at $27.81, down 2.15% on the day, but maintains a bullish technical outlook with strong support at $27. Fundamentally, the company reported robust Q2 2026 earnings of $1.21 per share, beating estimates, with net income surging to $144.9 million. Revenue growth accelerated to $1.2 billion in 2026, driving a net margin of 23.86%. Recent news highlights the termination of a vessel sale agreement with Diana Shipping, though operations remain unaffected.
The outlook for SBLK is positive, supported by strong profitability, a healthy balance sheet with a debt-to-asset ratio of 27.84%, and a shareholder-friendly dividend policy. Risks include exposure to volatile dry bulk shipping rates and competitive pressures. Analyst consensus is bullish with 58.34% buy ratings, indicating confidence in continued earnings momentum and valuation appeal at a P/E of 10.85.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
